Resolutions from the Annual General Meeting of Novo Nordisk A/S

• The Company's audited Annual Report 2014.
• The remuneration of the Board of Directors for 2014 and the level for 2015.
• Distribution of profit according to the adopted Annual Report 2014. The dividend will be DKK 5.00 per A and B share of DKK 0.20.

• Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors. 
• Re-election of Bruno Angelici, Liz Hewitt, and Thomas Paul Koestler as members of the Board of Directors. 
• Election of Sylvie Grégoire, Eivind Kolding and Mary Szela as new members of the Board of Directors.
• Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor. 

• Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 422,512,800 to DKK 412,512,800. 
• Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital. 

• Amendment to the Articles of Association to allow distribution of extraordinary dividend.
• Revised Remuneration Principles.

Further information